OT mobile menu

Search form


ASH 2015

ASH 57th Annual Meeting & Exposition

Stay connected with the OncoTherapy Network as we highlight some of the hottest topics in hematologic malignancies at the American Society of Hematology's 57th Annual Meeting & Exposition, December 5-8, 2015, in Orlando, Fla.

ASH 2015

Acalabrutinib (ACP-196), a second-generation BTK inhibitor, has demonstrated high response rates in patients with chronic lymphocytic leukemia (CLL) who have experienced relapse or refractory disease.

During the plenary session at the American Society of Hematology's (ASH) Annual Meeting on December 6, 2015, in Orlando, Fla., presenter Sébastien Maury, MD, PhD, had good news for the crowd anticipating the results of a multicenter trial.

Waseem Qasim, MBBS, PhD, and his team began researching a novel strategy to enable “off-the-shelf”’ therapy with mismatched donor chimeric antigen receptor (CAR)19 T cells.

A new study shows promise for patients with B-cell malignancies who receive allogeneic hematopoietic stem cell transplantation (alloHSCT).

Researchers have demonstrated in a phase II study, the efficacy of novel treatments for newly diagnosed multiple myeloma patients who are ineligible for stem cell transplantation.

Ahead of the 57th ASH Annual Meeting & Exposition, December December 5–8, 2015, Nitin Jain, MD, discusses the cost burden associated with targeted therapy use in the CLL population.

Ahead of the 57th ASH Annual Meeting & Exposition, December 5–8, 2015, Jeffrey Tyner, PhD, discusses his latest research on screening tumor cells derived from cancer patients to help guide better treatment decisions.

Subscribe to ASH 2015 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.